Publication Name	World Journal of Hepatology
Manuscript ID	15432
Country	France

Received	2014-11-27 10:56
Peer-Review Started	2014-11-29 12:24
To Make the First Decision	2014-12-12 17:33
Return for Revision	2014-12-18 14:30
Revised	2014-12-22 18:29
Second Decision	2015-01-14 08:30
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-01-20 16:51
Articles in Press	2015-01-20 16:51
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-04-13 14:20
Publish the Manuscript Online	2015-04-19 17:46

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Virology
Manuscript Type	Review
Article Title	Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade
Manuscript Source	Invited Manuscript
All Author List	Heidi Barth
Funding Agency and Grant Number
Corresponding Author	Dr. Heidi Barth, Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, 3 rue Koeberlé, 67000 Strasbourg, France. heidi.barth@chru-strasbourg.fr
Key Words	Pathogenesis; Host genetics; Direct-acting antivirals; Drug resistance; Vaccine; Hepatitis C virus
Core Tip	Twenty-five years after the discovery of hepatitis C virus (HCV) as the major cause of non-A, non-B post-transfusion hepatitis, we have entered a new era in HCV treatment that indicates the prospect of eradication of this important human pathogen. In this article, we will discuss the promising opportunities ahead and key future challenges in the era of new hepatitis C treatments, i.e., barriers in identifying HCV infected individuals, access to new HCV drugs, emergence of drug resistance, and the current status of HCV vaccine development.
Publish Date	2015-04-19 17:46
Citation	Barth H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol 2015; 7(5): 725-737
URL	http://www.wjgnet.com/1948-5182/full/v7/i5/725.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i5.725

Full Article (PDF)	WJH-7-725.pdf
Full Article (Word)	WJH-7-725.doc
Manuscript File	15432-Review.doc
Answering Reviewers	15432 Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	15432-Conflict-of-interest statement.pdf
Copyright License Agreement	15432-Copyright assignment.pdf
Peer-review Report	15432-Peer review(s).pdf
Scientific Misconduct Check	15432-CrossCheck.jpg
Scientific Editor Work List	15432-Scientific editor work list.pdf